Genomic chaos in peripheral blood lymphocytes of Hodgkin's lymphoma patients one year after ABVD chemotherapy/radiotherapy
- PMID: 30260497
- DOI: 10.1002/em.22216
Genomic chaos in peripheral blood lymphocytes of Hodgkin's lymphoma patients one year after ABVD chemotherapy/radiotherapy
Abstract
Hodgkin's lymphoma (HL) is a lymphoid malignancy representing 5% of all cancers in children, 16% in adolescents, and 30-40% of all malignant lymphomas and has a survival rate of ~95% at 10 years. One of the most common treatment schemes uses a cocktail of genotoxic agents including adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) with or without radiotherapy. We investigated the occurrence of chromosomal damage in peripheral blood lymphocytes from five patients diagnosed with HL who provided samples before (BT), during chemotherapy (DT) and ~1 year after ABVD chemotherapy/radiotherapy (AT). Five healthy subjects served as controls. Chromosomal abnormalities were evaluated by multicolor fluorescence in situ hybridization. The average frequencies of structural chromosomal aberrations in HL samples were 0.11, 0.22, and 0.96 per cell in BT, DT, and AT samples, respectively. These frequencies were significantly different (P < 0.0001) with respect to control subjects (0.02 per cell). Interestingly, the highest frequency of structural damage, including genomic chaos and nonclonal abnormalities, was observed in the AT samples indicating that new aberrations were continuously produced. Rejoined structural chromosomal aberrations were the most common type of aberrations, although aneuploidies were also significantly increased. Finally, we found several chromosomal abnormalities linked to cancer secondary to treatment in all five HL patients. Our results show that ABVD chemotherapy plus radiotherapy is inducing genomic chaos in vivo; moreover, the persistence of genomic instability in the hematopoietic stem cells from HL patients may play a role in the occurrence of secondary cancer that is observed in 5-20% of HL patients. Environ. Mol. Mutagen. 59:755-768, 2018. © 2018 Wiley Periodicals, Inc.
Keywords: anticancer treatment; chromoplexia; genomic chaos; genomic instability; genotoxicity.
© 2018 Wiley Periodicals, Inc.
Comment in
-
Letter to the editor of environmental and molecular mutagenesis: In regard to Ramos et al.Environ Mol Mutagen. 2019 May;60(4):385-386. doi: 10.1002/em.22282. Environ Mol Mutagen. 2019. PMID: 30851116 No abstract available.
-
Genomic chaos in peripheral blood lymphocytes of hodgkins lymphoma patients 1 year after ABVD chemotherapy/radiotherapy.Environ Mol Mutagen. 2019 May;60(4):387-388. doi: 10.1002/em.22279. Environ Mol Mutagen. 2019. PMID: 30861193 No abstract available.
Similar articles
-
Nonclonal Chromosome Aberrations and Genome Chaos in Somatic and Germ Cells from Patients and Survivors of Hodgkin Lymphoma.Genes (Basel). 2019 Jan 10;10(1):37. doi: 10.3390/genes10010037. Genes (Basel). 2019. PMID: 30634664 Free PMC article. Review.
-
Characterizing Chemotherapy/Radiotherapy-Induced Genome Chaos in Hodgkin's Lymphoma Patients Using M-FISH.Methods Mol Biol. 2024;2825:247-262. doi: 10.1007/978-1-0716-3946-7_14. Methods Mol Biol. 2024. PMID: 38913314
-
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.N Engl J Med. 2011 Jul 21;365(3):203-12. doi: 10.1056/NEJMoa1100340. N Engl J Med. 2011. PMID: 21774708 Clinical Trial.
-
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.J Clin Oncol. 2003 Feb 15;21(4):607-14. doi: 10.1200/JCO.2003.12.086. J Clin Oncol. 2003. PMID: 12586796 Clinical Trial.
-
Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?Transfus Apher Sci. 2007 Aug;37(1):37-41. doi: 10.1016/j.transci.2007.04.004. Epub 2007 Aug 21. Transfus Apher Sci. 2007. PMID: 17714996 Review.
Cited by
-
The Spiral Model of Evolution: Stable Life Forms of Organisms and Unstable Life Forms of Cancers.Int J Mol Sci. 2024 Aug 23;25(17):9163. doi: 10.3390/ijms25179163. Int J Mol Sci. 2024. PMID: 39273111 Free PMC article. Review.
-
Chromoanagenesis in Osteosarcoma.Biomolecules. 2025 Jun 7;15(6):833. doi: 10.3390/biom15060833. Biomolecules. 2025. PMID: 40563473 Free PMC article. Review.
-
Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics.Biology (Basel). 2021 Aug 31;10(9):849. doi: 10.3390/biology10090849. Biology (Basel). 2021. PMID: 34571726 Free PMC article. Review.
-
Unclassified Chromosomal Abnormalities as an Indicator of Genomic Damage in Survivors of Hodgkin's Lymphoma.Cancers (Basel). 2025 Jul 23;17(15):2437. doi: 10.3390/cancers17152437. Cancers (Basel). 2025. PMID: 40805142 Free PMC article.
-
Nonclonal Chromosome Aberrations and Genome Chaos in Somatic and Germ Cells from Patients and Survivors of Hodgkin Lymphoma.Genes (Basel). 2019 Jan 10;10(1):37. doi: 10.3390/genes10010037. Genes (Basel). 2019. PMID: 30634664 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical